Previous clinical studies with the FDA-approved alpha-adrenergic antagonist, 23 phenoxybenzamine, showed apparent efficacy to reverse the symptoms and disabilities of the 24 neuropathic condition, Complex Regional Pain Syndrome; also, the anatomic spread and 25 intensity of this syndrome has a proliferative character and it was proposed that 26 phenoxybenzamine may have an anti-inflammatory, immunomodulatory mode of action. A 27 previous study gave evidence that phenoxybenzamine had anti-proliferative activity in 28 suppression of growth in several human tumor cell cultures. The same report demonstrated that 29 the drug possessed significant histone deacetylase inhibitory activity. Utilizing the 30 Harvard/Massachusetts Institute of Technology Broad Institute genomic database, CLUE, the 31 present study suggests that the gene expression signature of phenoxybenzamine in malignant cell 32 lines is consistent with anti-inflammatory/immunomodulatory activity and suppression of tumor 33 expansion by several possible mechanisms of action. Of particular note, phenoxybenzamine 34
Introduction

45
A previous study explored a possible anti-proliferative capacity of the drug, 46 phenoxybenzamine (PBZ), as a basis for its apparent therapeutic potential in the treatment of 47 It should be noted that the dataset in the earlier online platform of CMap was based almost 117 entirely on perturbations in only 3 tumor cell lines, including MCF7 (human breast 118 adenocarcinoma), PC3 (human prostate adenocarcinoma) and HL60 (human promyeloblast); the 119 first two cell lines are among the 9 in the current CLUE platform. In fact, in the case of PBZ, it 120 was only screened with the MCF7 and PC3 cell lines. 121 The scoring value obtained in the gene expression analyses is termed "tau;" it ranges from 122 100 to -100 and is a measure of the connectivity between the gene expression signature of the to PBZ is presented in Fig 2. Obviously, PBZ profiled against itself results in the highest score. 158 It should be noted that the median tau (connectivity) score for the 9 cell results and the summary 159 is reported in this output presentation. When searching this output in the cloud-based platform, 160 the tau scores for the individual cell results can be accessed by placing the cursor over the cell 161 result. This is an important feature of the software since it allows identification of the relative 162 connectivity for a query perturbagen with each of the 9 tumor cell types, which may be valuable 163 in recognizing specific mechanisms of action that may have therapeutic applications. When the detailed list option in Touchstone was queried for gene expression signatures that 178 had connectivity with PBZ it returned the gene set enrichment scores (2, 10) for groups of 179 compounds represented in defined PCL sets (Table 2) . A number of perturbagen classes of 180 biological interest were identified with group scores above 90; these are considered by the 181 program developers to be of strong interest in development of hypotheses for mechanisms of 182 action and therapeutic application; see: https://clue.ie/connectipedia/connectivity_scores. There 183 were no perturbagen classes that had group scores opposing the gene expression profiles of PBZ, 184 i.e., there were none with scores that were -90 or lower. The perturbagen classes are organized 185 initially on the basis of 3 or more perturbagens with the same mechanism of action. However, it 186 is essential that there is strong connectivity of gene expression signatures among all members of 187 a class; see: https://clue.io/connectopedia/pdf/pcls. Each of the perturbagen classes in Table 2 was examined in the Touchstone detailed list for 194 its members; these results are presented in Tables 3, 4, and 5. Only comparisons of PBZ with 195 chemical compounds/drugs (the CP class) were searched in these queries; this represented 2429 196 agents. For these analyses, all agents with connectivity scores above 85 when compared with 197 PBZ were included; for example, in the case of drugs with glucocorticoid agonist activity (Table   198 3) this included 30 of the 44 agents of that perturbagen class with this activity in the Touchstone 199 database. CSF1R, colony stimulating factor 1 receptor; DDR1, discoidin domain receptor 1; PDGFRA, platelet-derived growth factor receptor-alpha; TIE1, tyrosine kinase with immunoglobulin like and EGF like domains 1; ERBB2, ERBB4, receptor tyrosine kinases; KDR, kinase insert domain receptor; AKT1, serine-threonine protein kinase; NTRK1, neurotrophic tyrosine kinase receptor type 1; MAPK14, mitogen-activated protein kinase 14; NR1I2, nuclear receptor subfamily 1, group I, member 2; PRKCA, PRKCB, PRKCD, PRKCG, protein kinase C alpha, beta, delta, gamma; ALOX5, arachidonate 5-lipoxygenase; GSK3A, GSK3B, glycogen synthase kinase-3 alpha, beta; WEE1, nuclear tyrosine kinase (regulates entry into mitosis); CDK1, CDK2, CDK4, CDK5, CDK9, cyclin-dependent kinase 1, 2, 4, 5, 9; CDK5R1, cyclin dependent kinase 5 regulatory subunit 1; CCNE1, cyclin E1; LCK, lymphocyte specific protein tyrosine kinase; LRRK1, LRRK2, leucine-rich repeat kinase 1, 2; PGR, progesterone receptor; ESR1, estrogen receptor alpha; CYP17A1, CYP2C19, CYP2E1, cytochrome P450 17A1, 2C19, 2E1; NR3C2, mineralocorticoid receptor; CATSPER1, CATSPER2, CATSPER3, CATSPER4, cation channel sperm associated 1, 2, 3, 4; OPRK1, opioid receptor, kappa-1; TRPC5, transient receptor potential channel 5; AR, androgen receptor; SRD5A1, steroid-5-alpha-reductase, alpha. HDAC inhibitors were not represented as a PCL set in the initial output (Table 2) , but a 205 search of this class in the detailed list database of Touchstone yielded the connectivities with 206 PBZ for some of these agents ( Table 6 ). Confirmation of connectivity of PBZ with HDAC 207 inhibitors in the CLUE platform was consistent with our earlier report using the on-line version 208 of CMap, and where PBZ was shown to directly inhibit several HDAC enzymes (1). Table 2 presents the summary of sets of agents by defined perturbagen classes that showed 229 strong connectivity scores with PBZ. The most prominent class was glucocorticoid receptor 230 agonists; this was completely unanticipated since PBZ shows no resemblance to a steroid 231 chemical structure (Fig 1) . There are a total of 44 drugs with glucocorticoid receptor agonist 232 activity in the Touchstone database; the fact that so many individual glucocorticoids had 233 connectivity scores of 85 or greater (Table 3) expression signatures with PBZ is consistent with the anti-inflammatory/immunomodulatory 238 mechanism of action for PBZ that has been proposed from some of our work and that of others in 239 the neuropathic pain syndrome, CRPS (1, 14, 15, 19) . Its vasodilating effect is responsible for most of its relatively minor dose-related side effects of 264 hypotension, dizziness, nasal stuffiness and impotence; these effects appear to be self-limiting to 265 some extent with continued intake (14, 15, 23).
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The clinical use of PBZ for its smooth muscle relaxing effects on the urogenital tract is a 267 source of information on the tolerability of the drug with long-term administration. This is found 
Epidermal Growth Factor Receptor Inhibitors 291
Eight gene expression signatures for inhibitors of epidermal growth factor receptor (EGFR) 292 co-sorted strongly with PBZ (Table 4) . EGFR inhibition has become a major area of water retention and weight gain, an effect that is not prominent with bezafibrate (36).
338
The second PPAR agonist of recognized clinical importance that matched with PBZ gene for these drug and common anti-proliferative effects that they may share. As with so many 391 cancer chemotherapeutic drugs, the DNA synthesis inhibitors have serious adverse effects. It is 392 important to note a finding that we have not previously reported. In the effects of PBZ on human 393 cancer cell growth assays that were conducted for us by the National Cancer Institute (NCI60), 394 and reported in our previous study (1) , PBZ showed no lethality in any of the cell cultures at their 395 standard assay concentration of 10 µM. (Table 5 ). HSP90 inhibitors represent a current intense area of clinical investigation as 399 adjunctive agents for the treatment of multiple cancers. Radicicol, the highest scoring agent in relation to PBZ (Table 5) (Table 5) . 
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There is considerable interest in the potential for cannabinoids as anti-cancer drugs (54) (55). (Table 5 ). As with other HIV protease inhibitors, indinavir has a peptide similar 441 structure and is a competitive inhibitor of aspartyl protease. It is currently in clinical use but is 442 used less frequently today since it is not superior to other inhibitors of HIV protease and has 443 more concerns related to renal toxicity (58).
In an attempt to gain some insight into possible reasons for the overlap between gene 445 expression signatures for PBZ and indinavir, indinavir was queried as the index perturbagen in 446 Touchstone. The PCL sets that were returned as important for indinavir relative to the entire 447 database were not similar to any of those for PBZ (Table 2) . However, there were two PCL sets 448 for indinavir, "Norepinephrine reuptake inhibitor," and "Tricyclic antidepressant" that had high The HDAC inhibitor with the highest connectivity score to PBZ was phenylbutyrate ( Table   455   6 ). Phenylbutyrate is designated as an orphan drug by the FDA with applications in the 
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The next 4 HDAC inhibitors listed in Table 6 have various stages of experimental 463 investigation. Rhamnetin has been investigated for its anti-inflammatory effects; at a 464 concentration of 1 µM it caused significant inhibition of pro-inflammatory cytokines from 465 macrophages (60).
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N-hydroxy-7(2-naphthylthio) heptanomide (HNHA) was found to be more potent than potency to trichostatin-A on HDAC5 and 9 and greater inhibitory potency than SAHA on both 492 HDAC5 and 9. The selectivity of PBZ for inhibition of these HDACs is of interest in relation to 493 the fact that the high expression of HDAC5 and 9 in pediatric medulloblastoma tumors was 494 found to be prognostic for poor survival (69). These tumors are the most common pediatric 495 brain tumors. HDAC5 has also been shown to be a strong promotor of tumor migration and 
